FDA approves cure for sickle cell disease, the first treatment to use gene-editing tool CRISPR

Welcome to the Precious Metals Bug Forums

Welcome to the PMBug forums - a watering hole for folks interested in gold, silver, precious metals, sound money, investing, market and economic news, central bank monetary policies, politics and more. You can visit the forum page to see the list of forum nodes (categories/rooms) for topics.

Why not register an account and join the discussions? When you register an account and log in, you may enjoy additional benefits including no Google ads, market data/charts, access to trade/barter with the community and much more. Registering an account is free - you have nothing to lose!

searcher

morning
Moderator
Benefactor
Messages
12,097
Reaction score
2,606
Points
238

FDA approves cure for sickle cell disease, the first treatment to use gene-editing tool CRISPR​

The Food and Drug Administration on Friday approved a powerful treatment for sickle cell disease, a devastating illness that affects more than 100,000 Americans, the majority of whom are Black.

The therapy, called Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is the first medicine to be approved in the United States that uses the gene-editing tool CRISPR, which won its inventors the Nobel Prize in chemistry in 2020.

“I think this is a pivotal moment in the field,” said Dr. Alexis Thompson, chief of the division of hematology at Children’s Hospital of Philadelphia, who has previously consulted for Vertex. “It’s been really remarkable how quickly we went from the actual discovery of CRISPR, the awarding of a Nobel Prize, and now actually seeing it being an approved product.”

More:

 
Some old notes about CRISPR (caveat emptor) from June 2018:
Editing cells’ genomes with CRISPR-Cas9 might increase the risk that the altered cells, intended to treat disease, will trigger cancer, two studies published on Monday warn — a potential game-changer for the companies developing CRISPR-based therapies.

In the studies, published in Nature Medicine, scientists found that cells whose genomes are successfully edited by CRISPR-Cas9 have the potential to seed tumors inside a patient. That could make some CRISPR’d cells ticking time bombs, according to researchers from Sweden’s Karolinska Institute and, separately, Novartis.
...


A study at Karolinska Institutet in Sweden has revealed that CRISPR-Cas9 gene editing could favor mutations in the most common cancer-causing gene. What does it mean for the first CRISPR therapy trials in humans?

CRISPR-Cas9 has taken the life sciences field by storm, making gene editing simpler and faster than ever. Although CRISPR-Cas9 gene editing was only first described in 2012, the first human trials using CRISPR as a therapy were started in China last year and Europe is due to run the first one later this year. It seems like we might have rushed into it too soon, as a new study points out that therapies using this popular gene editing tool could inadvertently cause cancer.

The research, published today in Nature Medicine, describes that the use of CRISPR-Cas9 in human cells can activate the protein p53. This protein is involved in the repair of DNA breaks and can interfere with the efficiency of CRISPR to cut DNA.

This means that when selecting cells whose DNA has been correctly modified using CRISPR, those where p53 is mutated and therefore inactive will be more likely to be selected. Given that p53 mutations are the most common genetic alteration in cancer, the process used to modify and select CRISPR-edited cells could be favoring the selection of potentially cancerous cells.
...

 
The first treatment...? What was the jab all about anyway....?

an aside...

How do they reintroduce the altered gene into ones body? There are billions of genes to 'alter'... A shot in the arm? IV?
 
Back
Top Bottom